Hepatitis C virus infection: A single center experience

Bahrain Medical Bulletin

Volumn 30, Issue 1, 2008, Pages 3-8

  Abdulla, Maheeba A M ^a   Al Qamish, Jehad R A ^a  

^a SALMANIYA MEDICAL COMPLEX   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD TRANSFUSION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; MONOTHERAPY; PATIENT REFERRAL; POSTTRANSFUSION HEPATITIS; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

EID: 40549125262     PISSN: 10128298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Initiative for Vaccine Research, Viral Cancers, Hepatitis C. World Health Organization, 2006. (Accessed on April 20, 2007, at http://www.who.int/ vaccine_research/diseases/viral_cancers/en/index2.html).
2. Global Surveillance and Control of Hepatitis C. Report of a WHO Consultation Organized in Collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Viral Hepat 1999; 6:35-47.
3. Global Epidemiology of Hepatitis C Virus Infection. Lancet Infect Dis 2005; 5:558-67.
4. Palitzsch KD, Hottentrager B, Chlottmann K, et al. Prevalence of Antibodies against Hepatitis C Virus in the Adult German Population. Eur J Gastroenterol Hapatol 1999; 11:1215-20.
5. Zou S, Tepper M, El Saadany S. Prediction of Hepatitis C Burden in Canada. Can J Gastroenterol 2000; 14: 575-80.
6. Law MG, Dore GJ, Bath N, et al. Modeling Hepatitis C virus Incidence, Prevalence, and Long-term Sequelae in Australia, 2001. Int J Epidemiol 2003; 32: 717-24.
7. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
8. Frank C, Mohamed MK, Strickland GT, et al. The Role of Parenteral Antischistosomal Therapy in the Spread of Hepatitis C Virus in Egypt. Lancet 2000; 355:887-91.
9. Wasley A, Alter M. Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends. Semin Liver Dis 2000; 20: 1-16.
10. Seeff LB, Wright EC, Zimmerman HJ, et al. VA Cooperative Study of Post -Transfusion Hepatitis, 1969-1974: Incidence and Characteristics of Hepatitis and Responsible Risk Factors. Am J Med Sci 1975; 270: 355-62.
11. Dhingra N. Blood Safety in the Developing World and WHO Initiatives. Vox Sang 2002; 83:173-7.
12. Chakravarti A, Verma V, Kumaria R, et al. Anti-HCV Seropositivity among Multiple Transfused Patients with Beta Thalassemia. J Indian Med Assoc 2005; 103: 64-6.
13. Fried MW. Management of HCV in the Hemophilia Patient. Am J Med 1999;107:85S-9S.
14. Brettler DB, Alter HJ, Dienstag JL, et al. Prevalence of Hepatitis C Virus Antibody in a Cohort of Hemophilia Patients. Blood 1990; 76:254-6.
15. Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, et al. Hepatitis C Infection and Viremia in Dutch Hemophilia Patients. J Med Virol 1995; 45:241-6.
16. Troisi CL, Hollinger FB, Hoots WK, et al. A Multicenter Study of Viral Hepatitis in a United States Hemophilic Population. Blood 1993; 15(81):412-8.
17. Zarski JP, Bohn B, Bastie A, et al. Characteristics of Patients with Dual Infection by Hepatitis B and C viruses. J Hepatol 1998; 28:27-33.
18. Donato F, Boffetta P, Puoti M. A Meta-analysis of Epidemiological Studies on the Combined Effect of Hepatitis B and C Virus Infections in Causing Hepatocellular Carcinoma. Int J Cancer 1998; 75:347-54.
19. Everhart JE, Herion D. Hepatitis C Virus Infection and Alcohol. In: Liang T J, Hoofnagle J H, John I, et al. eds. Hepatitis C. San Diego: Academic Press, edition 2000; 363-5.
20. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of Alcohol on the Progression of Hepatitis C virus Infection: a Meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9.
21. Wheeler M. Ethanol and HCV-induced Cytotoxicity: the Perfect Storm. Gastroenterology 2005; 128:232-4.
22. Ramia S, Eid-Fares J. Distribution of Hepatitis C Virus Genotype in the Middle East. Int J Infect Dis 2006;10: 272-7.
23. Singh S, Malhotra V, Sarin SK. Distribution of Hepatitis C Virus Genotypes in Patients with Chronic Hepatitis C Infection in India. Indian J Med Res 2004; 119: 145-8.
24. Hosseini-Moghaddam SM, Keyvani H, Kasiri H, et al. Distribution of Hepatitis C Virus Genotypes among Hemodialysis Patients in Tehran - a Multicenter study. J Med Virol 2006; 78: 569-73.
25. Shobokshi OA, Serebour FE, Shakni Li. Hepatitis C Genotypes/subtypes among Chronic Hepatitis Patients in Saudi Arabia. Saudi Med J 2003; 24(2): S87-91.
26. Strader DB, Wright T, Thomas DL, et al. Diagnosis, Management, and Treatment of Hepatitis C. Hepatology. 2004;39:1147-71.
27. Lindsay KL. Introduction to Therapy of Hepatitis C. Hepatology. 2002; 36(suppl):S114-S20.
28. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C: 2002-10-12, 2002. Hepatology. 2002; 36(suppl):S3-S15.
29. Beltran M, Navas MC, De la Hoz F, et al. Hepatitis C Virus Seroprevalence in Multi-transfused Patients in Colombia. J Clin Virol 2005; 34(2): S33-8.
30. Alter MJ, Hadler SC, Judson FN, et al. Risk Factors for Acute Non-A, Non-B Hepatitis in the United States and Association with Hepatitis C Virus Infection. JAMA 1990; 264:2231-5.
31. Alter MJ. Epidemiology of Hepatitis C. Hepatology 1997; 26 (1): 62S-5S.
32. Al-Mahroos FT, Ebrahim A. Prevalence of Hepatitis B, Hepatitis C and Human Immune Deficiency Virus Markers among Patients with Hereditary Haemolytic Anaemias. Ann Trop Paediatr 1995; 15:121-8.
33. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between Hepatitis C Virus Genotypes and Sources of Infection in Patients with Chronic Hepatitis C. J Infect Dis 1995; 171:1607-10.
34. Shev S, Widell A, Foberg U, et al. HCV genotypes in Swedish Blood Donors as Correlated to Epidemiology, Liver Disease and Hepatitis C Virus Antibody Profile. Infection 1995; 23:253-7.
35. Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C Virus Type 1b (II) Infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122:161-8.
36. Zhou DX, Tang JW, Chu IM, et al. Hepatitis C Virus Genotype Distribution among Intravenous Drug User and the General Population in Hong Kong. J Medical Virology 2006; 78:574-81.
37. Desmond CP, Roberts SK, Dudley F, et al. Sustained Virological Response Rates and Durability of the Response to Interferon-based Therapies in Hepatitis C Patients Treated in the Clinical Setting. J Viral Hepat 2006; 13:311-5.
38. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med. 2002; 347(13):975-82.
39. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. N Engl J Med 2000; 343:1673-80.
40. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
41. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-9.